New stock news | DeMei Medicine submitted documents to the Hong Kong Stock Exchange, ranking first among Chinese innovative pharmaceutical companies in the number of indications covered by its skin disease products.

According to the disclosure by the Hong Kong Stock Exchange on April 22nd, Delmi Pharmaceuticals Limited (referred to as "Delmi Pharmaceuticals") submitted an application to the Hong Kong Stock Exchange for listing on the main board, with Huatai International as the sole sponsor. The prospectus shows that Delmi Pharmaceuticals is an innovative pharmaceutical company specializing in skin health, focusing on the integrated operation of research, production, and sales of prescription drugs and dermatological skincare products. The company is committed to providing comprehensive solutions for skin health from prevention, treatment to long-term care. The company has established a rich and differentiated product portfolio, covering major skin diseases with significant unmet clinical needs. According to the consultation report by Zhushi Consulting, among innovative drug companies in China, the number of skin disease indications covered by the company's products ranks first, and by 2024, the revenue generated from the company's prescription skin care products also ranks first. As of the last practical date, the company's major products and innovative pipeline are as follows: As of the last practical date: (i) in the field of prescription skin care products, Delmi Pharmaceuticals' major product pipeline includes three marketed products, four candidate products in clinical or late-stage development, and two preclinical candidate products, covering major skin diseases such as psoriasis, vitiligo, atopic dermatitis (AD), skin abrasions, superficial phlebitis, varicose veins, hidradenitis suppurativa (HS), nodular prurigo (PN), chronic spontaneous urticaria (CSU), etc.; and (ii) in the field of dermatological skincare products, the company's representative products include the He Zero Soothing series and the Xiliao Tu - Azelaic Acid series, primarily targeting consumers with atopic dermatitis and acne. According to the consultation report by Zhushi Consulting, the market size of the skin disease treatment and care market in China was 76.4 billion yuan in 2023, and is expected to grow at a compound annual growth rate of 10.6% from 2023 to 2035. With its strong collaborative research and development capabilities, highly integrated independent research and development capabilities, and industry-leading commercialization capabilities, the company is well prepared to seize the enormous market potential in the field of skin health. In terms of finance, in the fiscal years 2022, 2023, and 2024, Delmi Pharmaceuticals achieved revenues of approximately 384 million yuan, 473 million yuan, and 618 million yuan respectively; during the same period, the annual losses were 55.17 million yuan, 4.703 million yuan, and approximately 106 million yuan respectively.